Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

In a major advancement in the global fight against HIV, the World Health Organization (WHO) has recommended the use of ...

The World Health Organization (WHO) has recommended the global use of injectable lenacapavir (LEN) twice a year to provide near-total ...

The World Health Organisation (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative to daily pills and addressing the needs of key populations.

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Increasing the use of Apretude among Black women requires not only expanding awareness of the long-acting PrEP regimen in ...